Blueprint
FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of August
2018
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
AstraZeneca
prices a $3bn bond issue
15 August 2018 07:00 BST
AstraZeneca prices a $3bn bond issue
AstraZeneca PLC announces that, on 14 August 2018, it priced a four
tranche global bond offering totalling $3bn. The offering is
expected to close on 17 August 2018, subject to customary closing
conditions. AstraZeneca expects to use the net proceeds of the
issue for general corporate purposes, which may include the
refinancing of existing indebtedness. The transaction, which is a
global offering registered with the US Securities and Exchange
Commission (SEC), consists of the following four
tranches:
●
$0.85bn
of fixed rate notes with a coupon of 3.500%, maturing 17 August
2023;
●
$0.40bn
of floating rate notes with a coupon of 3 month LIBOR plus 0.665%,
maturing 17 August 2023;
●
$1.00bn
of fixed rate notes with a coupon of 4.000%, maturing 17 January
2029; and
●
$0.75bn
of fixed rate notes with a coupon of 4.375%, maturing 17 August
2048.
Citigroup, Deutsche Bank Securities, Goldman Sachs & Co. LLC
and J.P. Morgan acted as joint book-running managers on the
transaction. The notes will be issued under AstraZeneca's effective
shelf registration statement on Form F-3, which AstraZeneca filed
with the SEC on 22 November 2016. The offering is being made solely
by means of the prospectus contained within that shelf registration
statement, along with a prospectus supplement forming part of the
effective registration statement, which investors should
read.
A copy of the prospectus supplement and accompanying prospectus
relating to the offering can be obtained by contacting Citigroup
Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, by telephone at (800) 831-9146
or by email at prospectus@citi.com; Deutsche Bank Securities Inc.,
Attention: Prospectus Group, 60 Wall Street, New York, NY
10005-2836, by telephone at (800) 503-4611, or by email at
prospectus.cpdg@db.com; Goldman Sachs & Co. LLC, Prospectus
Department, 200 West Street, New York, NY 10282, by telephone at
1-866-471-2526, by facsimile at (212) 902-9316 or by emailing
Prospectus-ny@ny.email.gs.com or J.P. Morgan Securities LLC, 383
Madison Avenue, New York, NY 10179, Attention: Investment Grade
Syndicate Desk or by telephone collect at (212) 834-4533. You may
also download these documents for free by visiting EDGAR on the SEC
website at www.sec.gov.
This announcement shall not constitute an offer to sell or the
solicitation of an offer to buy the securities described herein,
nor shall there be any sale of these securities in any jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such jurisdiction.
The bond issuance does not impact the Company's financial guidance
for 2018.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that
focuses on the discovery, development and commercialisation of
prescription medicines, primarily for the treatment of diseases in
three therapy areas - Oncology, Cardiovascular, Renal &
Metabolism and Respiratory. AstraZeneca operates in over 100
countries and its innovative medicines are used by millions of
patients worldwide.
Cautionary Statements Regarding Forward-Looking
Statements
This announcement contains certain forward-looking statements with
respect to the operations, performance and financial condition of
AstraZeneca. Although we believe our expectations are based on
reasonable assumptions, any forward-looking statements, by their
very nature, involve risks and uncertainties and may be influenced
by factors that could cause actual outcomes and results to be
materially different from those predicted. The forward-looking
statements reflect knowledge and information available at the date
of preparation of this announcement and AstraZeneca undertakes no
obligation to update these forward-looking statements.
|
Media Relations
|
|
|
|
Karen
Birmingham
|
UK/Global
|
+44 203 749 5634
|
|
Rob
Skelding
|
UK/Global
|
+44 203 749 5821
|
|
Matt
Kent
|
UK/Global
|
+44 203 749 5906
|
|
Gonzalo
Viña
|
UK/Global
|
+44 203 749 5916
|
|
Jacob
Lund
|
Sweden
|
+46 8 553 260 20
|
|
Michele
Meixell
|
US
|
+1 302 885 2677
|
|
|
|
|
|
Investor Relations
|
|
|
|
Thomas
Kudsk Larsen
|
|
+44 203 749 5712
|
|
Josie
Afolabi
|
|
+44 203 749 5631
|
|
Craig
Marks
|
Finance; Fixed Income
|
+44 7881 615 764
|
|
Henry
Wheeler
|
Oncology
|
+44 203 749 5797
|
|
Mitchell
Chan
|
Oncology; Other
|
+1 240 477 3771
|
|
Christer
Gruvris
|
Cardiovascular; Metabolism
|
+44 203 749 5711
|
|
Nick
Stone
|
Respiratory; Renal
|
+44 203 749 5716
|
|
Jennifer
Kretzmann
|
Retail Investors
|
+44 203 749 5824
|
|
US
toll-free
|
|
+1 866 381 7277
|
|
|
|
|
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
15 August
2018
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|